Tranexamic Acid for Reducing Bruising After Dermal Filler

Recruiting in Palo Alto (17 mi)

Overseen by Daniel Cho, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Wisconsin, Madison

No Placebo Group

Prior Safety Data

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is: * Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection? Participants will receive the study medication along with the standard facial filler injection and complete surveys.

Eligibility Criteria

This trial is for individuals seeking facial filler injections and willing to participate in surveys. The study specifically includes those who are suitable candidates for dermal fillers with hyaluronic acid. Details on exclusion criteria were not provided, so it's important to contact the trial organizers for more information.

Inclusion Criteria

I am interested in getting facial filler injections.

English speaking

I am between 18 and 89 years old.

Exclusion Criteria

I am under 18 years old.

I am over 89 years old.

I am able to make my own medical decisions.

Treatment Details

Interventions

• Tranexamic Acid (Anti-fibrinolytic agent)

Trial Overview The study tests whether adding Tranexamic Acid (TXA) to Hyaluronic Acid (HA) can reduce bruising, swelling, and pain after HA facial filler injections compared to a saline placebo. Participants will receive standard filler treatment along with either TXA or placebo.

Participant Groups

Group I: Facial Filler Injection Experimental Treatment 3 Interventions

TXA plus HA injection in half of face, saline plus HA injection on other half of face

Tranexamic Acid is already approved in United States, European Union, Canada, Japan, Australia for the following indications:

🇺🇸 Approved in United States as Tranexamic Acid for:

• Heavy menstrual bleeding
• Prevention of excessive bleeding during surgeries

🇪🇺 Approved in European Union as Tranexamic Acid for:

• Heavy menstrual bleeding
• Prevention of excessive bleeding during surgeries
• Hereditary angioedema

🇨🇦 Approved in Canada as Tranexamic Acid for:

• Heavy menstrual bleeding
• Prevention of excessive bleeding during surgeries

🇯🇵 Approved in Japan as Tranexamic Acid for:

• Heavy menstrual bleeding
• Prevention of excessive bleeding during surgeries

🇦🇺 Approved in Australia as Tranexamic Acid for:

• Heavy menstrual bleeding
• Prevention of excessive bleeding during surgeries

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Wisconsin - Madison Madison, WI

Who Is Running the Clinical Trial?

University of Wisconsin, Madison Lead Sponsor

References